High-dose aripiprazole in treatment-resistant schizophrenia [3]

Journal of Clinical Psychiatry

Volumn 67, Issue 4, 2006, Pages 674-675

  Duggal, Harpeet S ^a   Mendhekar, Dattatreya N ^b  

^a Herrick Memorial Hospital   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; HALOPERIDOL; TRIFLUOPERAZINE;

ABSENCE OF SIDE EFFECTS; AKATHISIA; ANAMNESIS; CLINICAL FEATURE; CLINICAL TRIAL; DRUG HALF LIFE; DRUG MEGADOSE; DYSLIPIDEMIA; ELECTROCARDIOGRAM; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERGLYCEMIA; LETTER; NAUSEA; ORTHOSTATIC HYPERTENSION; PARANOID SCHIZOPHRENIA; PRIORITY JOURNAL; RELAPSE; SEIZURE; SELF REPORT; SIDE EFFECT; VOMITING; WEIGHT GAIN;

EID: 33646799118     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/jcp.v67n0420c     Document Type: Letter

References (6)

1. Abilify (aripiprazole). Physicians' Desk Reference. 60th ed. Montvale, NJ: Thomson PDR; 2006:916-922
2. Goodnick PJ. Higher than Physician's Desk Reference (US) doses on atypical antipsychotics. Expert Opin Drug Saf 2005;4:653-668
3. Carstairs SD, Williams SR. Overdose of aripiprazole. a new type of antipsychotic. J Emerg Med 2005;28:311-313
4. Yokoi F, Grunder G, Biziere K. et al. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission and [11C]raclopride. Neuropsychopharmacology 2002;27:248-259
5. Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol 2004;24:192-208
6. Pierre JM, Wirshing DA, Wirshing WC. High-dose quetiapine in treatment refractory schizophrenia. Schizophr Res 2005;73:373-375